In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Balancing Act: Early Hints at a Biosimilars

This article was originally published in RPM Report

Executive Summary

FDA opened the regulatory phase of the biosimilar debate by hearing from industry and other stakeholders about what an approval system should look like. But this information-gathering session wasn’t all one-sided: FDA officials offered some hints of what they are thinking too. And while there are some significant areas of disagreement—and outlier positions—there was also quite a bit of common ground.
Advertisement

Related Content

Copaxone And Complex Generics: Difficult-To-Copy Does Not Mean Impossible
Much “Ado” About Biosimilars
Believing In Biosimilars: Industry Takes Long View on FDA Pathway
Believing In Biosimilars: Industry Takes Long View on FDA Pathway
Preparing for the Arrival of Follow-On Biologics
Preparing for the Arrival of Follow-On Biologics
Big Pharma May Be Big Player in Follow-On Biologics Market
Orphaning Biotech? The Impact of Biosimilars on Biotech Investment
Biosimilars: The Time Has Come

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS080756

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel